# To Evaluate the Effect and Safety of Telitacicept and Standard Treatment for 6months in IgA Nephropathy

> **NCT07098897** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **The Affiliated Hospital of Xuzhou Medical University** · enrollment: 150 (actual)

## Conditions studied

- IgA Nephropathy (IgAN)

## Interventions

- **DRUG:** Telitacicept 160mg
- **DRUG:** Corticosteroid
- **DRUG:** ACE Inhibitor or Angiotensin receptor antagonist

## Key facts

- **NCT ID:** NCT07098897
- **Lead sponsor:** The Affiliated Hospital of Xuzhou Medical University
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-08-01
- **Primary completion:** 2025-05-25
- **Final completion:** 2025-09-30
- **Target enrollment:** 150 (ACTUAL)
- **Last updated:** 2025-08-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07098897

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07098897, "To Evaluate the Effect and Safety of Telitacicept and Standard Treatment for 6months in IgA Nephropathy". Retrieved via AI Analytics 2026-07-02 from https://api.ai-analytics.org/clinical/NCT07098897. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*